Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease
- PMID: 20403949
- DOI: 10.1177/1538574410362922
Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease
Abstract
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-reductase) inhibitors, otherwise known as statins, are currently the medical treatment of choice for hypercholesterolemia. Hypercholesterolemia is a known risk factor for cardiovascular disease, and statin therapy has led to a significant reduction in morbidity and mortality from adverse cardiac events, stroke, and peripheral arterial disease. In addition to achieving a therapeutic decrease in serum cholesterol levels, statin therapy appears to promote other effects that are independent of changes in serum cholesterol. These ''pleiotropic'' effects include attenuation of vascular inflammation, improved endothelial cell function, stabilization of atherosclerotic plaque, decreased vascular smooth muscle cell migration and proliferation, and inhibition of platelet aggregation. This article is part I of a 2-part review, and it focuses on the pleiotropic effects of statins at the cellular level.
Similar articles
-
Statin therapy--Part II: Clinical considerations for cardiovascular disease.Vasc Endovascular Surg. 2010 Aug;44(6):421-33. doi: 10.1177/1538574410363833. Epub 2010 Jun 14. Vasc Endovascular Surg. 2010. PMID: 20547576 Review.
-
Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?Nutr Metab Cardiovasc Dis. 2001 Oct;11(5):328-43. Nutr Metab Cardiovasc Dis. 2001. PMID: 11887430 Review.
-
Statin withdrawal: clinical implications and molecular mechanisms.Pharmacotherapy. 2006 Sep;26(9):1288-96. doi: 10.1592/phco.26.9.1288. Pharmacotherapy. 2006. PMID: 16945051 Review.
-
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.Pharmacotherapy. 2006 Jul;26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. doi: 10.1592/phco.26.7part2.85S. Pharmacotherapy. 2006. PMID: 16803418 Review.
-
[The pleiotropic effects of statins].Harefuah. 2005 Aug;144(8):577-82, 597. Harefuah. 2005. PMID: 16146158 Review. Hebrew.
Cited by
-
Pitavastatin attenuates hypercholesterolemia-induced decline in serotonin transporter availability.Lipids Health Dis. 2024 Aug 17;23(1):250. doi: 10.1186/s12944-024-02236-4. Lipids Health Dis. 2024. PMID: 39154177 Free PMC article.
-
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.Ther Adv Endocrinol Metab. 2024 Jul 25;15:20420188241252309. doi: 10.1177/20420188241252309. eCollection 2024. Ther Adv Endocrinol Metab. 2024. PMID: 39071115 Free PMC article. Review.
-
The role of autophagy in SIM mediated anti-inflammatory osteoclastogenesis through NLRP3 signaling pathway.Immun Inflamm Dis. 2024 Jan;12(1):e1145. doi: 10.1002/iid3.1145. Immun Inflamm Dis. 2024. PMID: 38270300 Free PMC article.
-
Inhibitory Effects of Simvastatin on IL-33-Induced MCP-1 via the Suppression of the JNK Pathway in Human Vascular Endothelial Cells.Int J Mol Sci. 2023 Aug 21;24(16):13015. doi: 10.3390/ijms241613015. Int J Mol Sci. 2023. PMID: 37629196 Free PMC article.
-
Statins in Cirrhosis: Trial Data Are in but the Jury Is Still Out.Dig Dis Sci. 2023 Aug;68(8):3216-3217. doi: 10.1007/s10620-023-07970-w. Epub 2023 May 22. Dig Dis Sci. 2023. PMID: 37213002 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
